PECATI二期试验最终分析11月13日报道:43名晚期胸腺肿瘤患者中位总生存40.2个月,3年生存率53%,三级以上治疗相关不良事件44.2%

二期临床试验 PECATI 的最终分析11月13日对外报道,结果发表于《Journal of Thoracic Oncology》。试验由法国 Gustave Roussy 的 Jordi Remon 等研究者开展,评估仑伐替尼联合帕博利珠单抗用于经治晚期 B3 型胸腺瘤与胸腺癌患者。
试验为多中心、单臂设计,共入组43名在至少一线含铂化疗后进展的转移性患者,其中84%为胸腺癌、16%为 B3 型胸腺瘤。治疗方案为仑伐替尼每日口服20毫克,加帕博利珠单抗每三周静脉输注200毫克,最多35个周期。
中位随访24.6个月时,中位无进展生存期为22.1个月,高于早期分析的14.9个月;中位总生存期为40.2个月,3年生存率为53%。客观缓解率为25.6%,含1例完全缓解;疾病控制率为93%。
安全性方面,三级以上治疗相关不良事件发生率为44.2%,27.9%的患者因治疗相关毒性停用至少一种研究药物,免疫相关不良事件发生率为39.5%。研究者指出,样本量小且为单臂设计,结果不能证明该联合方案优于其他治疗,后续仍需前瞻性研究确认。
图中是胸腺的位置与组织结构示意图,PECATI 试验入组的胸腺瘤与胸腺癌正是起源于胸腺的肿瘤。
Final PECATI Phase 2 Analysis, Reported November 13: Median Overall Survival of 40.2 Months in 43 Patients With Advanced Thymic Tumors, 53% Alive at Three Years, and Grade 3 or Higher Treatment-Related Events in 44.2%
The final analysis of the Phase 2 PECATI trial was reported on November 13 and published in the Journal of Thoracic Oncology. Led by Jordi Remon of Gustave Roussy in France, the trial evaluated lenvatinib plus pembrolizumab in previously treated patients with advanced B3-thymoma and thymic carcinoma.
The multicenter, single-arm study enrolled 43 patients with metastatic disease who had progressed after at least one platinum-based chemotherapy regimen; 84% had thymic carcinoma and 16% had B3-thymoma. Treatment consisted of oral lenvatinib 20 mg daily plus intravenous pembrolizumab 200 mg every three weeks, for up to 35 cycles.
At a median follow-up of 24.6 months, median progression-free survival was 22.1 months, up from 14.9 months in the earlier analysis, and median overall survival was 40.2 months, with 53% of patients alive at three years. The objective response rate was 25.6%, including one complete response, and the disease control rate was 93%.
On safety, grade 3 or higher treatment-related adverse events occurred in 44.2% of patients, 27.9% discontinued at least one study drug because of treatment-related toxicity, and immune-related adverse events occurred in 39.5%. The investigators note that the small sample size and single-arm design mean the results cannot establish that the combination is superior to other treatments, and that further prospective studies are needed.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:2206 The Location Structure and Histology of the Thymus. Cropped.png — Author: OpenStax College. Licensing: CC BY 3.0.
GSM Global · 本篇英文版 English edition of this story

